Boston Scientific Corporation (NYSE:BSX) price on Thursday, August 26, fall -0.11% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $44.76.
A look at the stock’s price movement, the level at last check in today’s session was $44.81, moving within a range at $44.455 and $45.3055. The beta value (5-Year monthly) was 0.88 while the PE ratio in trailing twelve months stood at 121.77. Turning to its 52-week performance, $46.28 and $32.99 were the 52-week high and 52-week low respectively. Overall, BSX moved -1.54% over the past month.
Boston Scientific Corporation’s market cap currently stands at around $63.56 billion, with investors looking forward to this quarter’s earnings report slated for Oct 26, 2021 – Nov 01, 2021. Analysts project the company’s earnings per share (EPS) to be $0.4, which has seen fiscal year 2021 EPS growth forecast to increase to $1.61 and about $1.87 for fiscal year 2022. Per the data, EPS growth is expected to be 67.70% for 2021 and 16.10% for the next financial year.
Analysts have a consensus estimate of $3.02 billion for the company’s revenue for the quarter, with a low and high estimate of $2.96 billion and $3.09 billion respectively. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $12.03 billion, representing a 21.40% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that BSX is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
31 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 5 analyst(s) rate the stock as a Hold, 21 recommend BSX as a Buy and 5 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 5.69, with BSX’s current price about 0.51% and 2.02% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.10, while 7-day volatility ratio is 2.11% and 2.12% in the 30-day chart. Further, Boston Scientific Corporation (BSX) has a beta value of 0.89, and an average true range (ATR) of 0.98. Analysts have given the company’s stock an average 52-week price target of $51.20, forecast between a low of $45.00 and high of $55.00. Looking at the price targets, the low is -0.54% off recent price level in today’s trading while to achieve the yearly target high, it has to move -22.88%. Nonetheless, investors will most likely welcome a -16.18% jump to $52.00 which is the analysts’ median price.
In the market, a comparison of Boston Scientific Corporation (BSX) and its peers suggest the former has performed considerably weaker. Data shows BSX’s intraday price has changed -0.11% today and 13.04% over the past year. Comparatively, Abbott Laboratories (ABT) has moved 0.27% so far today and only 21.73% in the past 12 months. Looking at another peer, we see that Medtronic plc (MDT) price has dipped -0.85% on the day. However, the stock is 31.15% off its price today a year ago. Moreover, Stryker Corporation (SYK) is also down -0.16% in today’s trading while keeping a an uptrend of 43.21% over the past year. If we look at the PE ratio, we find that Boston Scientific Corporation’s ratio stands at 121.77 compared to Abbott Laboratories’s 34.91 and Medtronic plc’s 50.56. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.36% and -0.17% respectively on the day as seen in early trades.
If we refocus on Boston Scientific Corporation (NYSE:BSX), historical trading data shows that trading volumes averaged 7.38 million over the past 10 days and 6.63 million over the past 3 months. The company’s latest data on shares outstanding shows there are 1.42 billion shares.
The 0.30% of Boston Scientific Corporation’s shares are in the hands of company insiders while institutional holders own 93.90% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.4 million on May 27, 2021, giving us a short ratio of 1.51. The data shows that as of May 27, 2021 short interest in Boston Scientific Corporation (BSX) stood at 0.80% of shares outstanding, with shares short falling to 16.62 million registered in Apr 29, 2021. Current price change has pushed the stock 24.65% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BSX stock continues to rise going into the next quarter.